Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

John­son & John­son’s Janssen said Wednes­day that its bis­pe­cif­ic an­ti­body Ry­bre­vant (ami­van­tam­ab-vmjw) in com­bo with laz­er­tinib met its dual pri­ma­ry end­points …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.